Indication: 1. This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. 2. It is used for trauma or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 3. It is used as an antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase. 4. It is used for fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism, as well as menorrhagia caused by pathological increased local fibrinolysis in the uterine cavity. 5. It is used for mild bleeding caused by central nervous system diseases, such as subarachnoid hemorrhage and intracranial aneurysm bleeding. The use of this product is better than other antifibrinolytic drugs in stopping bleeding, but

Indication: 1. This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. 2. It is used for trauma or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 3. It is used as an antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase. 4. It is used for fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism, as well as menorrhagia caused by pathological increased local fibrinolysis in the uterine cavity. 5. It is used for

Indication: 1. This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. 2. It is used for trauma or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 3. It is used as an antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase. 4. It is used for fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism, as well as menorrhagia caused by pathological increased local fibrinolysis in the uterine cavity. 5. It is used for mild bleeding caused by central nervous system diseases, such as subarachnoid hemorrhage and intracranial aneurysm bleeding. The use of this product is superior to other anti-fibrotic drugs in stopping bleeding.

Indication: 1. This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. This product is generally not used for secondary hyperfibrinolytic state caused by disseminated intravascular coagulation before heparinization. 2. It is used for trauma or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 3. It is used as an antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase. 4. It is used for fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism, as well as menorrhagia caused by pathological increased local fibrinolysis in the uterine cavity. 5. It is used for mild bleeding caused by central nervous system diseases, such as subarachnoid hemorrhage and intracranial aneurysm bleeding. This product is better than other antifibrinolytic drugs for hemostasis, but

Indication: 1. This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. 2. It is used for trauma or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 3. It is used as an antagonist of tissue plasminogen activator (t-PA), streptokinase, and urokinase. 4. It is used for fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism, as well as menorrhagia caused by pathological increased local fibrinolysis in the uterine cavity. 5. It is used for

Indication: MRI enhancement of the central nervous system and other parts. For normal brain tissue, there is no enhancement due to the presence of the blood-brain barrier; but the dura mater, choroid plexus, and pituitary gland may be enhanced. In addition to the central nervous system, other parts can also be applied. It can significantly increase the signal intensity of liver cancer and hepatic vascular cysts; distinguish liver cysts from normal liver tissue; diagnose or differentiate acute, subacute and chronic myocardial infarction, congenital heart disease, and dissecting aneurysms; it is also helpful for the diagnosis of nasopharyngeal carcinoma, breast cancer, and kidney tumors.

Indication: MRI enhancement of the central nervous system and other parts. For normal brain tissue, there is no enhancement due to the presence of the blood-brain barrier; but the dura mater, choroid plexus, and pituitary gland may be enhanced. In addition to the central nervous system, other parts can also be applied. It can significantly increase the signal intensity of liver cancer and hepatic vascular cysts; distinguish liver cysts from normal liver tissue; diagnose or differentiate acute, subacute and chronic myocardial infarction, congenital heart disease, and dissecting aneurysms; it is also helpful for the diagnosis of nasopharyngeal carcinoma, breast cancer, and kidney tumors.

Indication: MRI enhancement of the central nervous system and other parts. For normal brain tissue, there is no enhancement due to the presence of the blood-brain barrier; but the dura mater, choroid plexus, and pituitary gland may be enhanced. In addition to the central nervous system, other parts can also be applied. It can significantly increase the signal intensity of liver cancer and hepatic vascular cysts; distinguish liver cysts from normal liver tissue; diagnose or differentiate acute, subacute and chronic myocardial infarction, congenital heart disease, and dissecting aneurysms; it is also helpful for the diagnosis of nasopharyngeal carcinoma, breast cancer, and kidney tumors.

Indication: This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. This product is also suitable for: 1. Traumatic or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 2. Used as an antagonist of tissue plasminogen activator (t→PA), streptokinase, and urokinase. 3. Fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism. 4. Excessive menstruation, hyphema hemorrhage, and severe epistaxis caused by pathologically increased local fibrinolysis in the uterine cavity. 5. Mild bleeding caused by rupture of a central aneurysm, such as subarachnoid hemorrhage and intracranial aneurysm bleeding.

Indication: This product is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis. For secondary hyperfibrinolytic state caused by disseminated intravascular coagulation, this product is generally not used before heparinization. This product is also suitable for: 1. Traumatic or surgical bleeding in organs rich in plasminogen activators such as the prostate, urethra, lungs, brain, uterus, adrenal glands, and thyroid glands. 2. Used as an antagonist of tissue plasminogen activator (t→PA), streptokinase, and urokinase. 3. Fibrinolytic bleeding caused by artificial abortion, early placental abruption, stillbirth, and amniotic fluid embolism. 4. Excessive menstruation, hyphema hemorrhage, and severe epistaxis caused by pathologically increased local fibrinolysis in the uterine cavity. 5. Mild bleeding caused by rupture of a central aneurysm, such as subarachnoid hemorrhage and intracranial aneurysm bleeding.